ECSP099251A - PHARMACEUTICAL FORMULATIONS - Google Patents

PHARMACEUTICAL FORMULATIONS

Info

Publication number
ECSP099251A
ECSP099251A EC2009009251A ECSP099251A ECSP099251A EC SP099251 A ECSP099251 A EC SP099251A EC 2009009251 A EC2009009251 A EC 2009009251A EC SP099251 A ECSP099251 A EC SP099251A EC SP099251 A ECSP099251 A EC SP099251A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulations
active agent
formulation
release
salt
Prior art date
Application number
EC2009009251A
Other languages
Spanish (es)
Inventor
Yi Gao
R Ju Tzuchi
Dennis Y Lee
Nicole Nguyen
Hauiliang Wu
Original Assignee
Abbott Lab
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Fournier Lab Ireland Ltd filed Critical Abbott Lab
Publication of ECSP099251A publication Critical patent/ECSP099251A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una formulación de liberación modificada que comprende un agente activo en una matriz de polímero hidrofílico en donde el agente activo es una sal de ácido fenofíbrico en donde la velocidad de liberación de la formulación en una disolución in vitro es considerablemente independiente de la fuerza iónica de los medios de disolución.The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the rate of release of the formulation in an in vitro solution is considerably independent of the ionic strength of dissolution media.

EC2009009251A 2006-10-12 2009-04-13 PHARMACEUTICAL FORMULATIONS ECSP099251A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12

Publications (1)

Publication Number Publication Date
ECSP099251A true ECSP099251A (en) 2009-06-30

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009251A ECSP099251A (en) 2006-10-12 2009-04-13 PHARMACEUTICAL FORMULATIONS

Country Status (14)

Country Link
EP (1) EP2081563A1 (en)
JP (1) JP2010506855A (en)
KR (1) KR20090119959A (en)
CN (1) CN101677981A (en)
AU (1) AU2007307641A1 (en)
CA (1) CA2672686A1 (en)
CO (1) CO6160302A2 (en)
EA (1) EA200900531A1 (en)
EC (1) ECSP099251A (en)
IL (1) IL198160A0 (en)
MX (1) MX2009003815A (en)
SG (1) SG175570A1 (en)
WO (1) WO2008046052A1 (en)
ZA (1) ZA200902488B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435564B2 (en) * 2008-05-30 2013-05-07 Ucb Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
CN102304103A (en) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 Fenofibrate acid salt, preparation method, pharmaceutical composition and application
CN102659570B (en) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 Difluoro fenofibrate acid and pharmaceutically acceptable salt thereof as well as preparation method and application thereof
FR3050112B1 (en) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq USE OF FENOFIBRIC ACID IN THE TREATMENT OF HEPATIC DISEASES
CN107496397A (en) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 A kind of compound and its preparation of melbine and Fenofibric Acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2356549C2 (en) * 2002-12-17 2009-05-27 Эббетт ГмбХ унд Ко.КГ Composition containing phenofibrin acid, its physiologically acceptable salt or derivative
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1829541A1 (en) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts

Also Published As

Publication number Publication date
IL198160A0 (en) 2009-12-24
MX2009003815A (en) 2009-09-07
AU2007307641A1 (en) 2008-04-17
CA2672686A1 (en) 2008-04-17
ZA200902488B (en) 2010-10-27
CO6160302A2 (en) 2010-05-20
EA200900531A1 (en) 2009-12-30
WO2008046052A1 (en) 2008-04-17
KR20090119959A (en) 2009-11-23
EP2081563A1 (en) 2009-07-29
CN101677981A (en) 2010-03-24
JP2010506855A (en) 2010-03-04
SG175570A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
ES2524320T3 (en) Composition for the prevention or treatment of disease associated with thrombus or embolus
CY1120888T1 (en) TRANSPARENT PHARMACEUTICAL COMPOSITIONS INCLUDING ACTIVE AGENTS
ES2557303T3 (en) Therapeutic agent for spinal canal stenosis
NI201300054A (en) ENCLOSED CONTROLLED RELEASE DOSE FORMS RESISTANT TO IMPROPER HANDLING
CL2009001490A1 (en) Intrauterine delivery system comprising a progestagen or a drug with progestagenic activity and a therapeutically active substance selected from naproxen, indomethacin, ibuprofen, mefenamic acid or flurbiprofen, with the ability to prevent or suppress abnormal and / or irregular bleeding.
CR10404A (en) PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION ON THE BASIS OF A LIBERATION SYSTEM THAT INCLUDES AN ACID-SOLUBLE POLYMER AND A PH-DEPENDENT POLYMER
ECSP099251A (en) PHARMACEUTICAL FORMULATIONS
AR058620A1 (en) PHARMACEUTICAL FORMULATION FOR THE SUPPLY OF INHIBITING COMPOUNDS OF THE THYROSINE KINASE RECEPTOR (RTKI) TO THE EYE
WO2009066146A3 (en) Stable solutions of sparingly soluble actives
PE20091574A1 (en) DRUG ADMINISTRATION SYSTEM WITH STABILIZING EFFECT
PE20141539A1 (en) A NEW THERAPEUTIC COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE PRINCIPLE
BR112013004455A2 (en) compositions for gastric delivery of active agents
CO6140021A2 (en) PHARMACEUTICAL COMPOSITION OF MODIFIED RELEASE OF A RELAXING MUSCLE AND AN NSAID
NI201100119A (en) SILDENAFIL PULSATILE RELEASE COMPOSITION AND PROCESS TO PREPARE IT.
ES2563632T3 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients intravenously
PE20130374A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING IBUPROFEN
BR112013006632A2 (en) improved drug delivery delivery compositions and system
ES2491565T3 (en) Transfection agent
CL2012001545A1 (en) Aqueous pharmaceutical compositions comprising an ester of a prostanoid, a carboxylic acid between 1,2,1,6% dibasic sodium phosphate, sodium chloride, a solubilizing agent, and the rest of water, with a pH ranging from 4 to 8; use in eye disorders such as glaucoma, diabetic retinopathy, uveitis, among others.
AR086491A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING FEXOFENADINE
UY29637A1 (en) FORMULATION OF PROLONGED RELEASE OF ACTIVE PRINCIPLES OF MEDICINES
FR2937867B1 (en) PHARMACEUTICAL ASSOCIATION CONTAINING LIPOIC ACID AND HYDROXYCITRIC ACID AS ACTIVE INGREDIENTS.
BRPI0608083A2 (en) composition comprising ocaperidone
BRPI0821975B8 (en) TRANSDERMAL THERAPEUTIC SYSTEM (TTS) FOR DELIVERING ACTIVE PHARMACEUTICAL SUBSTANCES THROUGH THE SKIN, PROCESS FOR PREPARING A TRANSDERMAL THERAPEUTIC SYSTEM AND USE OF A POLYMERIC LAYER CONTAINING ACTIVE SUBSTANCE
AR070617A1 (en) PHARMACEUTICAL FORMULATION INCLUDING OXABISPIDINS / 236